{"seq": 1, "variant": "treatment", "cmd": "pm --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm - PubMed CLI tools for AI agents\n\nUsage: pm <command> [OPTIONS]\n\nRecommended workflow:\n  pm quick       Search + fetch + parse in one command (RECOMMENDED)\n  pm filter      Filter JSONL articles by year, journal, author, etc.\n\nAll commands:\n  quick       Search + fetch + parse in one command (RECOMMENDED)\n  search      Search PubMed, return PMIDs\n  fetch       Fetch PubMed XML by PMIDs\n  parse       Parse PubMed XML to JSONL\n  filter      Filter JSONL articles by field patterns\n  cite        Fetch CSL-JSON citations\n  download    Download full-text PDFs\n  diff        Compare two JSONL files by PMID\n  audit       View audit trail and PRISMA report\n  init        Initialize audit trail and cache (.pm/)\n\nExamples:\n  pm quick \"CRISPR cancer\" --max 100 > results.jsonl\n  pm filter --year 2024 --has-abstract < results.jsonl\n\nTip: save results to a file so you can reuse them without re-searching:\n  pm quick \"my query\" > results.jsonl\n  pm filter --year 2024 < results.jsonl\n  pm filter --has-doi < results.jsonl\n\nUse 'pm <command> --help' for command-specific help.\n", "stderr": "", "elapsed_s": 0.284, "ts": 1771589068.1333787}
{"seq": 2, "variant": "treatment", "cmd": "pm quick --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm quick - Quick PubMed search (outputs JSONL)\n\nUsage: pm quick [OPTIONS] \"search query\"\n\nOptions:\n  --max N         Maximum results (default: 100)\n  -v, --verbose   Show progress on stderr\n  -h, --help      Show this help message\n\nOutput:\n  JSONL to stdout (one article per line)\n\nExamples:\n  pm quick \"CRISPR cancer therapy\"\n  pm quick --max 20 \"machine learning diagnosis\"\n\nFor advanced filtering, use the full pipeline:\n  pm search \"query\" | pm fetch | pm parse | pm filter --year 2024\n", "stderr": "", "elapsed_s": 0.342, "ts": 1771589076.237723}
{"seq": 3, "variant": "treatment", "cmd": "pm quick CAR-T cell therapy for B-cell lymphoma --max 100 -v", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41705912\", \"title\": \"Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe.\", \"authors\": [\"Tan Yan Zhi\", \"Breislin Emily\", \"Woods Matthew\", \"Madin-Warburton Matthew\", \"Gladwell Daniel\", \"Zang Alexandra\", \"Vadgama Sachin\", \"Doble Brett\", \"Wiesinger Adriana\", \"Sola-Morales Oriol\"], \"journal\": \"Journal of medical economics\", \"year\": \"2026\", \"date\": \"2026-12\", \"abstract\": \"Despite clinical efficacy and cost-effectiveness, time to reimbursement for chimeric antigen receptor (CAR) T-cell therapies varies greatly across Europe. We examined these differences, and quantified potential patient benefits with faster access. A targeted literature search collated reimbursement statuses for all approved CAR T-cell therapy indications by 1 October 2024. Time to reimbursement decision (TTRD), defined as time between marketing authorization and published reimbursement decision, was assessed. By benchmarking against the TTRD of the three fastest countries, patient impact, in the form of potential gains in lives, life-years (LYs) and long-term survivors, for the first three approved indications for CAR T-cell therapies were estimated. Each outcome was multiplied by population size, incidence, CAR T-cell eligibility, and market share to obtain population-level impact. Scenario analyses were conducted by examining different TTRD assumptions. Across 12 identified indications for CAR T-cell therapy, France, Germany, and Switzerland had the fastest TTRD, compared to Denmark, the Netherlands, and Ireland which had the slowest. Among an estimated annual incident population of 6,594 across 3\u2009L\u2009+\u2009diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and pediatric acute lymphoblastic leukemia (ALL), 1,199 lives, 1,222 long-term survivorships, and 37,229 LYs, could potentially be gained by ensuring time to access across these countries was equivalent to the fastest three assessors in these 3L\u2009+\u2009DLBCL, MCL, and pediatric ALL. Access to CAR T-cell therapies varied widely across European count", "stderr": "Searching PubMed: \"CAR-T cell therapy for B-cell lymphoma\" (max 100)...\nFetching batch 1 (100 PMIDs)...\n", "elapsed_s": 1.885, "ts": 1771589086.5813012}
{"seq": 4, "variant": "treatment", "cmd": "pm filter --year 2024 --has-abstract", "exit_code": 0, "stdin_lines": 0, "stdout": "", "stderr": "", "elapsed_s": 0.248, "ts": 1771589100.9971817}
{"seq": 5, "variant": "treatment", "cmd": "pm filter --year 2024 --has-abstract", "exit_code": 0, "stdin_lines": 101, "stdout": "", "stderr": "", "elapsed_s": 0.219, "ts": 1771589107.0042646}
{"seq": 6, "variant": "treatment", "cmd": "pm filter --has-abstract", "exit_code": 0, "stdin_lines": 101, "stdout": "{\"pmid\": \"41705912\", \"title\": \"Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe.\", \"authors\": [\"Tan Yan Zhi\", \"Breislin Emily\", \"Woods Matthew\", \"Madin-Warburton Matthew\", \"Gladwell Daniel\", \"Zang Alexandra\", \"Vadgama Sachin\", \"Doble Brett\", \"Wiesinger Adriana\", \"Sola-Morales Oriol\"], \"journal\": \"Journal of medical economics\", \"year\": \"2026\", \"date\": \"2026-12\", \"abstract\": \"Despite clinical efficacy and cost-effectiveness, time to reimbursement for chimeric antigen receptor (CAR) T-cell therapies varies greatly across Europe. We examined these differences, and quantified potential patient benefits with faster access. A targeted literature search collated reimbursement statuses for all approved CAR T-cell therapy indications by 1 October 2024. Time to reimbursement decision (TTRD), defined as time between marketing authorization and published reimbursement decision, was assessed. By benchmarking against the TTRD of the three fastest countries, patient impact, in the form of potential gains in lives, life-years (LYs) and long-term survivors, for the first three approved indications for CAR T-cell therapies were estimated. Each outcome was multiplied by population size, incidence, CAR T-cell eligibility, and market share to obtain population-level impact. Scenario analyses were conducted by examining different TTRD assumptions. Across 12 identified indications for CAR T-cell therapy, France, Germany, and Switzerland had the fastest TTRD, compared to Denmark, the Netherlands, and Ireland which had the slowest. Among an estimated annual incident population of 6,594 across 3\u2009L\u2009+\u2009diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and pediatric acute lymphoblastic leukemia (ALL), 1,199 lives, 1,222 long-term survivorships, and 37,229 LYs, could potentially be gained by ensuring time to access across these countries was equivalent to the fastest three assessors in these 3L\u2009+\u2009DLBCL, MCL, and pediatric ALL. Access to CAR T-cell therapies varied widely across European count", "stderr": "", "elapsed_s": 0.291, "ts": 1771589128.0825908}
{"seq": 7, "variant": "treatment", "cmd": "pm filter --year 2024", "exit_code": 0, "stdin_lines": 101, "stdout": "", "stderr": "", "elapsed_s": 0.24, "ts": 1771589152.5905347}
{"seq": 8, "variant": "treatment", "cmd": "pm audit", "exit_code": 1, "stdin_lines": 0, "stdout": "", "stderr": "Error: No .pm/ directory found. Run 'pm init' first.\n", "elapsed_s": 0.296, "ts": 1771589167.9565806}
{"seq": 9, "variant": "treatment", "cmd": "pm --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm - PubMed CLI tools for AI agents\n\nUsage: pm <command> [OPTIONS]\n\nRecommended workflow:\n  pm quick       Search + fetch + parse in one command (RECOMMENDED)\n  pm filter      Filter JSONL articles by year, journal, author, etc.\n\nAll commands:\n  quick       Search + fetch + parse in one command (RECOMMENDED)\n  search      Search PubMed, return PMIDs\n  fetch       Fetch PubMed XML by PMIDs\n  parse       Parse PubMed XML to JSONL\n  filter      Filter JSONL articles by field patterns\n  cite        Fetch CSL-JSON citations\n  download    Download full-text PDFs\n  diff        Compare two JSONL files by PMID\n  audit       View audit trail and PRISMA report\n  init        Initialize audit trail and cache (.pm/)\n\nExamples:\n  pm quick \"CRISPR cancer\" --max 100 > results.jsonl\n  pm filter --year 2024 --has-abstract < results.jsonl\n\nTip: save results to a file so you can reuse them without re-searching:\n  pm quick \"my query\" > results.jsonl\n  pm filter --year 2024 < results.jsonl\n  pm filter --has-doi < results.jsonl\n\nUse 'pm <command> --help' for command-specific help.\n", "stderr": "", "elapsed_s": 0.417, "ts": 1771589187.7259881}
{"seq": 10, "variant": "treatment", "cmd": "pm filter --year 2024 --has-abstract", "exit_code": 0, "stdin_lines": 101, "stdout": "", "stderr": "", "elapsed_s": 0.297, "ts": 1771589345.8006556}
{"seq": 11, "variant": "treatment", "cmd": "pm filter --has-abstract", "exit_code": 0, "stdin_lines": 101, "stdout": "{\"pmid\": \"41705912\", \"title\": \"Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe.\", \"authors\": [\"Tan Yan Zhi\", \"Breislin Emily\", \"Woods Matthew\", \"Madin-Warburton Matthew\", \"Gladwell Daniel\", \"Zang Alexandra\", \"Vadgama Sachin\", \"Doble Brett\", \"Wiesinger Adriana\", \"Sola-Morales Oriol\"], \"journal\": \"Journal of medical economics\", \"year\": \"2026\", \"date\": \"2026-12\", \"abstract\": \"Despite clinical efficacy and cost-effectiveness, time to reimbursement for chimeric antigen receptor (CAR) T-cell therapies varies greatly across Europe. We examined these differences, and quantified potential patient benefits with faster access. A targeted literature search collated reimbursement statuses for all approved CAR T-cell therapy indications by 1 October 2024. Time to reimbursement decision (TTRD), defined as time between marketing authorization and published reimbursement decision, was assessed. By benchmarking against the TTRD of the three fastest countries, patient impact, in the form of potential gains in lives, life-years (LYs) and long-term survivors, for the first three approved indications for CAR T-cell therapies were estimated. Each outcome was multiplied by population size, incidence, CAR T-cell eligibility, and market share to obtain population-level impact. Scenario analyses were conducted by examining different TTRD assumptions. Across 12 identified indications for CAR T-cell therapy, France, Germany, and Switzerland had the fastest TTRD, compared to Denmark, the Netherlands, and Ireland which had the slowest. Among an estimated annual incident population of 6,594 across 3\u2009L\u2009+\u2009diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and pediatric acute lymphoblastic leukemia (ALL), 1,199 lives, 1,222 long-term survivorships, and 37,229 LYs, could potentially be gained by ensuring time to access across these countries was equivalent to the fastest three assessors in these 3L\u2009+\u2009DLBCL, MCL, and pediatric ALL. Access to CAR T-cell therapies varied widely across European count", "stderr": "", "elapsed_s": 0.268, "ts": 1771589352.0468364}
